Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

Published:2011-06 Issue:6 Volume:9 Page:1191-1199
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

TIEDE A.,FRIEDRICH U.,STENMO C.,ALLEN G.,GIANGRANDE P.,GOUDEMAND J.,HAY C.,HOLMSTRÖM M.,KLAMROTH R.,LETHAGEN S.,MCKENZIE S.,MIESBACH W.,NEGRIER C.,YUSTE V. J.,BERNTORP E.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2011.04293.x/fullpdf

Reference36 articles.

1. Mechanism of action, development and clinical experience of recombinant FVIIa;Hedner;J Biotechnol,2006

2. Mechanism of action of recombinant activated factor VII: an update;Hedner;Semin Hematol,2006

3. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. The NovoSeven (F7HAEM-1505) Investigators;Hoots;Haemophilia,2008

4. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors;Konkle;J Thromb Haemost,2007

5. Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study;Robinson;Postgrad Med J,1993

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders;Nature Cardiovascular Research;2024-02-08

2. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors;Clinical Pharmacology & Therapeutics;2024-01-16

3. Immunogenicity of Therapeutic Proteins;Protein-based Therapeutics;2023

4. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1);Journal of Thrombosis and Haemostasis;2019-11-15

5. Establishment of an HPLC-based method to identify key proteases of proteins in vitro;Analytical Biochemistry;2019-05